Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.

Martin S. Tallman,Francesco Lo-Coco,Gisoo Barnes,Morgan Kruse,Rebecca Wildner,Monique Martin,U. Mueller,Boxiong Tang

Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.

2015

Martin S. Tallman
Francesco Lo-Coco
Gisoo Barnes
Morgan Kruse
Rebecca Wildner
Monique Martin
U. Mueller
Boxiong Tang

Introduction This study estimated the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment.

Keywords:

Oncology
Immunology
Arsenic trioxide
Cost-effectiveness analysis
Pharmacology
Internal medicine
Acute promyelocytic leukemia
Retinoic acid
Medicine
Tretinoin
cost effectiveness
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations